571 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education

    • Science
    • 4.6 • 9 Ratings

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Liana G. Apostolova, MS, MD, FAAN - Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?

    Liana G. Apostolova, MS, MD, FAAN - Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?

    Go online to PeerView.com/JYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder affecting 10% of people over age 65 and increasing in global prevalence. Recent advances in disease-modifying therapies have opened the door to the possibility of treatment approaches that can slow or prevent disease progression and improve patient outcomes. Now, with several anti–amyloid beta (Aβ) monoclonal antibodies in late-stage development, there is hope for families, clinicians, and researchers. The greatest likelihood of treatment success lies in timely diagnosis and early intervention. In this activity, based on a live symposium held at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases in Barcelona, Spain, an international panel of experts will discuss the importance of early recognition and diagnosis of AD and present the latest evidence on validated and emerging biomarkers that can aid in the early diagnosis of AD. They will also explore the mechanisms of action, efficacy, and safety data for promising disease-modifying therapies in development for the treatment of AD. Using patient case examples to frame the discussion, the expert faculty panel will provide practical guidance on how clinicians can effectively and safely integrate new diagnostic tools and disease-modifying therapies into clinical practice. Upon completion of this activity, participants should be better able to: Describe the rationale for identifying patients at risk for Alzheimer’s disease (AD) early in the disease course, Utilize validated neuroimaging techniques and molecular biomarkers to make early and accurate neuropathological diagnoses of AD, Select appropriate AD patients who may benefit from novel disease-modifying therapies based on an understanding of their respective mechanisms of action, efficacy, and safety profiles.

    • 1 hr 44 min
    Bruce Cree, MD, PhD, MAS - Leveraging the Power of Anti-CD20 mAbs in Patient-Centric Multiple Sclerosis Care

    Bruce Cree, MD, PhD, MAS - Leveraging the Power of Anti-CD20 mAbs in Patient-Centric Multiple Sclerosis Care

    Go online to PeerView.com/JWS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in multiple sclerosis discusses the use of anti-CD20 monoclonal antibodies in the treatment of relapsing MS. Upon completion of this activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Assess the mechanisms of action, safety, and efficacy of anti-CD20 monoclonal antibodies used to treat relapsing forms of MS, Apply best practices and clinical evidence when using B cell–depleting therapies to optimize outcomes for patients with relapsing MS, Implement treatment plans designed to maximize COVID-19 vaccination efficacy in patients being treated for MS with anti-CD20 medications.

    • 29 min
    Jonathan Corren, MD - Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma

    Jonathan Corren, MD - Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma

    Go online to PeerView.com/FSQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of airway hyper-responsiveness in severe uncontrolled asthma. Upon completion of this activity, participants should be better able to: Compare the pathophysiology of airway inflammation with airway hyper-responsiveness (AHR) and their clinical manifestations in patients with severe asthma, Apply insights with regard to the role of AHR, as well as recent clinical evidence concerning the efficacy of biologic agents in addressing AHR, to the management of patients with severe asthma.

    • 27 min
    Brett King, MD, PhD - Addressing Healthcare Disparities and Optimizing Patient Outcomes in Atopic Dermatitis and Alopecia Areata: Expert Insight on How to Improve Access and Quality of Care

    Brett King, MD, PhD - Addressing Healthcare Disparities and Optimizing Patient Outcomes in Atopic Dermatitis and Alopecia Areata: Expert Insight on How to Improve Access and Quality of Care

    Go online to PeerView.com/TJZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss strategies to optimize patient outcomes in atopic dermatitis and alopecia areata. Upon completion of this activity, participants should be better able to: Appropriately diagnose atopic dermatitis (AD) and alopecia areata (AA) and assess severity to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities, Describe current and emerging treatments for AD and AA in the context of mechanism of action, efficacy and safety profile, dosage and administration, and other factors relevant to clinical use, Utilize available resources to identify and overcome racial and ethnic health disparities in the management of AD and AA and ultimately improve health outcomes in under-represented populations.

    • 1 hr 25 min
    Rajiv Agarwal, MD, MS - A Renewed Look at MRA Therapy: Improving Renal Outcomes and Reducing Risks in Patients With Type 2 Diabetes

    Rajiv Agarwal, MD, MS - A Renewed Look at MRA Therapy: Improving Renal Outcomes and Reducing Risks in Patients With Type 2 Diabetes

    Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.

    • 36 min
    Sarina Elmariah, MD, PhD, MPH - Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options

    Sarina Elmariah, MD, PhD, MPH - Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options

    Go online to PeerView.com/DTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules symmetrically distributed on the trunk and extremities. PN is defined by intense pruritus lasting ≥6 weeks, history of repeated scratching, and subsequent development of pruritic, elevated, firm, and nodular skin lesions, in a vicious itch–scratch cycle. The intense itch associated with PN leads to sleep disturbances and reduced social participation and work productivity, resulting in a drastically reduced quality of life and psychosocial disturbances. Unfortunately, these issues experienced among patients with PN are further compounded by the lack of effective treatment options. In this activity, based on a recent live educational symposium, a panel of experts addresses real-world questions and dilemmas faced by providers and the PN patients for whom they care. By providing practical guidance on how to effectively integrate the latest evidence and expert recommendations into real-world clinical scenarios, this activity provides participating clinicians with the necessary tools to effectively navigate the rapidly changing landscape for PN. Additionally, patient videos are utilized throughout to convey key information regarding the burden of PN and optimal management strategies. Upon completion of this activity, participants should be better able to: Discuss the impact on quality of life and economic implications of prurigo nodularis (PN), Describe the pathophysiology of PN as it relates to clinically relevant disease mechanisms and novel therapeutic targets, Evaluate emerging treatment options for PN in the context of mechanism of action, efficacy, and safety, Treat PN in accordance with current evidence and expert recommendations, recognizing that an effective treatment approach should be based on clinical judgment and tailored to the individual needs of the patient.

    • 42 min

Customer Reviews

4.6 out of 5
9 Ratings

9 Ratings

Albeamy ,

Fix titles!

Your titles are so long I can't see what the podcast is about without playing it and watching the long title scroll along my screen. That makes your podcasts too difficult to access to be useful.

Top Podcasts In Science

Hidden Brain
Alie Ward
Jordan Harbinger
Neil deGrasse Tyson
PRX and Greater Good Science Center
Sam Harris

You Might Also Like

PVI, PeerView Institute for Medical Education
The Curbsiders Internal Medicine Podcast
The Clinical Problem Solvers
The New England Journal of Medicine
Core IM Team
JAMA Network